The Latest Breaking News from AbbVie Inc

Biopharma giant AbbVie (ABBV) is well-placed to gain from its drug pipeline, recent drug approvals, and strategic acquisitions. Given its strong fundamentals, discounted valuation, high profitability, reliable dividends, and favorable analyst estimates, investing in this stock could help you retire earlier. Read more.

Leading biopharmaceutical company AbbVie Inc. (ABBV) is well-positioned to benefit from its diversified portfolio, research breakthroughs, drug and therapy approvals, acquisitions, and partnerships. The company has been increasingly paying dividends, supported by its stable earnings stream. Therefore, investors looking for passive income amid uncertain market conditions could invest in this…

Rising concerns over stubbornly-high inflation and the Fed’s commitment to bring it down to its desired level have kept equities under pressure lately. Amid increasing recessionary concerns, investing in blue-chip stocks such as Procter & Gamble (PG), AbbVie (ABBV), Pfizer (PFE), Dow (DOW), and Walgreens Boots Alliance (WBA) could help…

The stock market has been under pressure amid the high inflation and the Fed’s hawkish tilt. The Fed launched another 75 basis-point rate hike on Wednesday and indicated that it would keep increasing rates to bring down inflation to the target level. Thus, we think fundamentally solid stocks AbbVie (ABBV),…

The Fed’s continued monetary policy tightening and consequent recession fears are expected to keep the stock market under pressure in the upcoming months. However, bullish traders could keep paying with fundamentally strong stocks The Coca-Cola Company (KO), AbbVie (ABBV), and Merck & Co. (MRK). Read more….

August CPI figures indicate that inflation is yet to be controlled, and the Fed might launch another significant interest rate hike next week. As recessionary fears loom over the economy, it might be ideal for seniors to invest in the fundamentally sound stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and…

The stock market is expected to remain under immense pressure in the near term as the Federal Reserve hints at reiterating its stance of raising interest rates until inflation falls to the target level. Given an uncertain economic outlook, investors may want to make their portfolios sturdy by adding high-quality…

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

Thanks to better-than-expected corporate earnings and the expectation that inflation will cool off, the stock market rebounded from the lows in the year's first half. However, inflation remains elevated, so the Fed is expected to continue its aggressive interest rate hikes. Given this backdrop, investors could cushion their portfolios by…